We aim to be a global healthcare leader, going beyond the Korean market
Growth to a global healthcare group
Present ~ 2010
- 2019
- Acquired International Quality Management System Standard ISO9001
- Completed phase 3 clinical tests for the next-generation gastroesophageal reflux disease medicine, ‘Fexuprazan’
- Received ‘Best 100 Companies to Work at in Korea’ award
- Received Minister of Employment and Labor Award at the ‘2019 Company Togetherness Awards & CSR Film Festival’
- Government Innovative Pharmaceutical Company award
- Launched proprietarily developed botulinum toxin ‘Nuceiva’ (Canadian product name) in Canada
- Received sales permit in Europe for proprietarily developed botulinum toxin ‘Nuceiva’ (European product name)
- Acquired International Environmental Safety and Health Certification 'ISO 14001', 'ISO 45001'
- US FDA designated new pulmonary fibrosis drug DWN12088 as rare drug
- Founded ‘Don’t Wait Project Volunteer Corps 1’ for the healthy life of people with developmental disorders
- URSA 300mg’, acquired indication for ‘prevention of gallstone after stomach incision’ for the first time in the world
- Officially launched proprietarily developed botulinum toxin ‘Jeuveau’ (US product name) in the US
- Launched ‘Olomax’ which simultaneously targeting high blood pressure and hyperlipidemia
- Officially opened ‘Daewoong Pharmaceutical News Room’
- ‘Nabota’ phase 3 clinical trial results in US was published in SCI-level international academic journal
- Investment cooperation with Vietnam’s largest pharmaceutical company ‘Traphaco’
- New pulmonary fibrosis drug DWN12088 selected as government-supported project
- Hyangnam plant acquired International Safety Health Management System Standard ISO 45001
- Internally developed botulinum toxin approved by USFDA, being the first in Asia
- 2018
- Acquired Anti-Corruption Management System ‘ISO 37001’
- Quality Circle received Presidential Gold and Silver Award at the ‘National Quality Management Convention’
- Nabota acquired the first eye wrinkle indication among domestic botulinum toxin
- Quality Circle received the first Grand Prize at the 2018 International Convention on QC Circles (ICQC2018) in the pharmaceutical industry
- Established ‘Health Life/Technology Coexistence Fund’
- Nabota plant received EU GMP approval
- Nabota plant received Canadian GMP approval
- Established ‘Daewoong Infion’ bio research center in Indonesia
- New drug DWP14012 selected as government-supported project
- Nabota plant received cGMP approval in the US
- Chairman Yoon Jae-seung, Vice-chairman Lee Jong Wook resigned
- Yoon Jae-Chun, Jeon Sengho appointed as CEO to begin professional management system
- 2017
- 'Daewoong Infion’ selected as the best bio pharmaceutical company award
- Completed Nabota Plant 2 with 4.5 million vials production capability annually
- Completed construction of the Osong Plant in Chungbuk with high-tech cGMP facilities
- Hyangnam plant re-certified as ‘2017 Gyeonggi Good Work Place Company (GGWP)’
- 2016
- Acquired certification for Outstanding Human Resource Development Institute
- Daewoong Pharmaceutical Research Center ‘Daewoong Bio Center’ completed
- Prime Minister’s Citation for 'Good Gender Equality Employment Company’
- Antibiotic 'Daewoong Meropenem Injection' acquired US FDA approval
- Received ‘AA’ rating for two consecutive years from the Fair Trade Commission’s '2016 CP ratings'
- 2015
- Began construction of new plant in Osong, Chungbuk with cGMP levels
- Honorary Chairman Yoon Young-hwan received ‘Most Respected Entrepreneur of Korea Award’
- Established ‘Ggeumteul Ggeumteul Playground’, an obstacle-free playground at Seoul Children’s Park
- Began co-operation with Hanol Bio Pharma
- Completed the ‘Daewoong Infion’ bio plant in Indonesia
- Received Presidential Award on Fair Trade Day
- Olostar received ‘Technology Award’ at the 16th Korean New Drug Awards, New Drug Development Sector
- Received CP rating of ‘AA’
- Inauguration of Lee Jong Wook as vice-chairman
- 2014
- Received Prime Minister’s Award in science technology at the ‘Korean New Growth Management Awards’
- ‘Nabota’ selected as world-class product (MOTIE, KOTRA)
- Selected for the ‘2014 Gyeonggi Good Work Place Company’ (Gyeonggi Small and Medium Business Center, Gyeonggi-do)
- Established ‘Daewoong Pharmaceutical Liaoning Research Institute’ in China
- Established Japanese corporation
- Inauguration of Yoon Jae-seung as chairman, and Yoon Young-hwan as honorary chairman
- Received AA in corporate credit rating
- Selected as ‘work-study program’ company (HRD Korea)
- Launched botulinum toxin ‘Nabota’ in Korea
- Launched new compound Olmesartan-Rosuvastatin drug 'Olostar' in Korea
- Received ‘Technology Export Award’ at the Korean Drug Development Awards (Korea Drug Research Association)
- 2013
- Received Prime Minister’s Award for Family-friendly Company
- Acquired 2013 Family-friendly Company certification
- Received 2013 Innovative Pharmaceutical Company Award
- Acquired Chinese pharmaceutical company ‘Baifeng’ to establish Liaoning Daewoong Pharmaceutical
- Credit rating predicted to be upgraded to A+Positive
- Registered utility model for the ‘Caretropin Pen Injection’ in Russia
- 2012
- Established ‘Daewoong-Infion’ joint-venture in Indonesia
- Established corporation in India
- ‘Caretropin Pen Injection’ received ‘2011-2012 World Star Award’
- Selected for the Global Corporate Fostering Project in 'World Class 300'
- Selected as 'Innovative Pharmaceutical Company’
- 2011
- Opened the first in-company childcare facility in pharmaceutical industry ‘Little Bear Day Care Center’
- Pen injection received Minister of Knowledge and Economy
- URSA and Albis received quality certification (GH)
- Family-friendly company certification extended to the end of 2013
- 2010
- URSA selected as world-class product
- Implemented world’s first herpes labialis treatment with recurrence prevention effects
Daewoong introduced its outstanding R&D capabilities by developing "first-in-class“ and "best-in-class" products
2009 ~ 2000
- 2009
- Next-generation pain killer new drug DWP05195 began clinical trials
- Established pharmaceutical research institute in India
- Received Prime Minister’s Award at the 'National Productivity Awards’
- Established US corporation
- 2008
- Established corporation in Thailand
- Acquired outstanding family-friendly company from Ministry of Health, Welfare and Family Affairs
- Awarded at National Productivity Awards (leadership, innovation activities sector)
- Established obstacle-free playground at the National Assembly‘s day care center
- Received appreciation plaque from Yongwol-gun office for the Yongwol ‘1 Company 1 Village' program
- Received ‘Korean Association on Smoking and Health Chairman’s Appreciation Plaque’ on No Smoking Day
- Easyef received the first international common name certified from WHO
- 2007
- Established corporation in the Philippines
- Corporate credit rating upgraded to A+
- Selected as outstanding labor-management culture company
- Selected as outstanding company for productivity improvement at the Productivity and Innovation Awards
- Released Korea’s first 100mg high-content CoQ10
- Released high-content vitamin B compound ‘Impactamin Power’
- 2006
- Established branch in China
- Minister of Health and Welfare award for family-friendly company
- Established obstacle-free playground at Seoul Forest
- Lee Jong Wook inaugurated as CEO
- 2005
- Established corporation in Indonesia
- 'Daewoong Coenzyme Q10' awarded by Minister of Health and Welfare Award at the Health Industry Technology Conference
- 'Daewoong Coenzyme Q10' received Jang Young-shil Award
- Appreciation plaque during parliamentary inspection by the Health and Welfare Committee
- 2004
- Established Vietnam office
- Donation to Beautiful Store (Nonhyeon Store)
- 2003
- Daewoong Pharmaceutical Hyangnam Plant acquired ISO14001
- Hyangnam Plant acquired International Safety Health Management System certification OHSAS18001
- Completed high-tech automated logistics center / implemented APS system
- Successfully developed Coenzyme Q10 for the second time in the world
- 2002
- Grand Prize at the Korea Digital Awards
- Received Economic Justice Award
- Daewoong and Daewoong Pharmaceutical split up
- 2001
- Easyef received KT (New Technology Certification Mark)
- Launched world’s first number 1 biotechnology new drug Easyef which is developed in Korea
- 2000
- Hyangnam plant certified as outstanding manufacturing plant (KAIST)
Bold R&D investments and entered of new drug development
1999 ~ 1990
- 1999
- Entered phase 2 for Easyef
- 1998
- Chairman Yoon Young-hwan received Order of Civil Merit, Camellia Medal
- Implemented enterprise resource planning (ERP) system
- 1997
- Yoon Jae-seung inaugurated as CEO
- Easyef won the Chungmugong Patent Technology Award
- Received Minister of Education Award at the Industry-Academic Cooperation Awards
- 1996
- Received Facility Management Award at the National Quality Convention
- Received Minister of Education Award at the Industry-Academic Cooperation Awards
- 1995
- Began full operation of the Management Information System
- 1994
- Received Economic Justice Award
- Sales exceeded 100 billion KRW
- Lee Cheol-bae appointed as honorary chairman
- 1992
- Received Prime Minister’s Award on Labor Day
- Completed Hyangnam KGMP plant 2
- 1991
- Prime Minister’s Award at the Industry Promotion Agency Quality Master Awards
- Labor Peace Award (Labor and Industriousness Award) from Central Labor Economic Research Institute
- Received Outstanding Trademark Award from the Korea Intellectual Property Office
- Received Presidential Award by the Ministry of Labor on Labor Day
- Received Appreciation Plaque at the 37th General Conference of the Korean Pharmaceutical Association
-
The first exports, in pharmaceutical industry, to the Soviet Union
- 1990
- Received Korea International Trade Association Chairman Award for increased exports
- Received presidential award for the 5 million USD export tower
- Received silver medal (indirect sector) Prime Minister’s Award at the National Quality Management Circle Convention
Built foundation for technological partnerships and ventures with foreign companies
1989 ~ 1980
- 1989
- Received gold medal (direct sector) Prime Minister’s Award at the National Quality Management Circle Convention
- Received gold medal at the National Quality Management Convention
- Developed Pharmaceutical Medical Journal Management Program (PMS)
- 1988
- Moved HQ to Samseong-dong
- 1987
- Received Order of Iron Tower Industry for labor-management sector
- Received Order of Iron Tower Industry for science technology sector
- Received Minister of Health and Society Award for increased exports of pharmaceutical products
- Received presidential award on Science Day (Order of Iron Tower Industry)
- Received presidential award for 2 million USD export
- Received presidential award on Labor Day Received (Order of Iron Tower Industry)
- Received the first genetic engineering patent in Korea
- 1986
- Received Minister of Health and Society Award for export contributions
- Designated as KGMP-eligible company
- URSA - Designated as official provider for Asian Games and the ‘88 Seoul Olympics
- 1985
- Yoon Young-hwan appointed as chairman, Lee Cheol-bae appointed as president
- 1984
- Received approval to establish central research institute
- Completed construction of Daewoong Lilly Plant
- 1983
- Employees began to move-in into new employee apartments
- Received Korea Management Awards (education)
-
Established central research institute
- 1982
- Established Daewoong Lilly Pharmaceutical
- Received Order of Gold Tower Industry on Tax Day
- 1981
- Moved HQ to Seocho-dong
- 1980
- Sales exceeded 10 billion KRW
Growth to Korea’s top pharmaceutical company
1979 ~ 1970
- 1979
- Completed production facilities for injection-type antibiotics, opened hospital department
- 1978
-
Changed company name to Daewoong Pharmaceutical
- 1977
- Excellence award at the Corporate Public Announcement Conference
- 1976
- Raw materials and technology partnership with Gitse Siraimasu Pharmaceutical of Japan
- Began publication of Daewoong Newsletter
- 1974
- Establish Subsidiary Pharmaceutical Research Center
- 1973
- IPO (4th in pharmaceutical industry)
- 1972
- Completed Seongnam plant and moved HQ to Seoul
Daewoong’s dream to build a national company that can contribute to society
1969 ~ 1945
- 1966
- Yoon Young-hwan appointed as CEO
- 1961
- Changed company name to Daehan Vitamin Industries (CEO Park Moon-soo, capital 10 million KRW)
-
Launched URSA
- 1959
- Moved to new building in Choeup-dong, Busan
- 1954
- Approval for pharmaceutical product manufacturing (Ministry of Health and Society No. 43)
- 1949
- Received Vice President Award at the outstanding domestic product exhibit for the first time in Korea
- 1945
- Founded Joseon Ganyu Pharmaceutical Company